

# United States Patent and Trademark Office

UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Address: COMMISSIONER FOR PATENTS P.O. Box 1450 Alexandria, Virginia 22313-1450 www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
10/573,215	09/19/2006	Christian Birkner	22307-US	6868
22829 7590 · 09/07/2007 ROCHE MOLECULAR SYSTEMS INC			EXAMINER	
PATENT LAW DEPARTMENT			CHUNDURU, SURYAPRABHA	
1145 ATLANTIC AVENUE ALAMEDA, CA 94501		ART UNIT	PAPER NUMBER	
			1637	•
			MAIL DATE	DELIVERY MODE
			09/07/2007	PAPER

Please find below and/or attached an Office communication concerning this application or proceeding.

The time period for reply, if any, is set in the attached communication.

	Application No.	Applicant(s)			
	10/573,215	BIRKNER ET AL.			
Office Action Summary	Examiner	Art Unit			
	Suryaprabha Chunduru	1637			
The MAILING DATE of this communication app Period for Reply	ears on the cover sheet with the c	orrespondence address			
	VIC CET TO EVOIDE AMONTU	C) OR THIRTY (20) DAYS			
A SHORTENED STATUTORY PERIOD FOR REPLY WHICHEVER IS LONGER, FROM THE MAILING DOWN - Extensions of time may be available under the provisions of 37 CFR 1.11 after SIX (6) MONTHS from the mailing date of this communication.  If NO period for reply is specified above, the maximum statutory period vortice to reply within the set or extended period for reply will, by statute Any reply received by the Office later than three months after the mailing earned patent term adjustment. See 37 CFR 1.704(b).	ATE OF THIS COMMUNICATION 36(a). In no event, however, may a reply be tim vill apply and will expire SIX (6) MONTHS from , cause the application to become ABANDONE	N. nely filed the mailing date of this communication. D (35 U.S.C. § 133).			
Status					
1) Responsive to communication(s) filed on 23 A	<u>ugust 2007</u> .				
· <u> </u>	,—				
	Since this application is in condition for allowance except for formal matters, prosecution as to the merits is				
closed in accordance with the practice under E	Ex parte Quayle, 1935 C.D. 11, 45	53 O.G. 213.			
Disposition of Claims					
4)⊠ Claim(s) <u>1-8 and 13</u> is/are pending in the application.					
4a) Of the above claim(s) <u>13</u> is/are withdrawn f	rom consideration.				
5) Claim(s) is/are allowed.					
6)⊠ Claim(s) <u>1-8</u> is/are rejected.					
7) Claim(s) is/are objected to.					
8) Claim(s) are subject to restriction and/o	r election requirement.				
Application Papers					
9) The specification is objected to by the Examine	r.				
10)⊠ The drawing(s) filed on <u>24 March 2006</u> is/are: a	a) $igtii$ accepted or b) $igsqcup$ objected to	by the Examiner.			
Applicant may not request that any objection to the					
Replacement drawing sheet(s) including the correct					
11)☐ The oath or declaration is objected to by the Ex	aminer. Note the attached Office	Action or form PTO-152.			
Priority under 35 U.S.C. § 119					
12)⊠ Acknowledgment is made of a claim for foreign a)⊠ All b)□ Some * c)□ None of:	priority under 35 U.S.C. § 119(a)	-(d) or (f).			
1. Certified copies of the priority documents					
2. Certified copies of the priority documents	·				
3. Copies of the certified copies of the prior	·	ed in this National Stage			
application from the International Bureau  * See the attached detailed Office action for a list		d			
det the ditabled detailed office detail for a list	or the definied copies not receive	u.			
Attachment(s)					
Notice of References Cited (PTO-892)     Notice of Draftsperson's Patent Drawing Review (PTO-948)	4) Interview Summary Paper No(s)/Mail Da				
3) Information Disclosure Statement(s) (PTO/SB/08) Paper No(s)/Mail Date 6/12/06.	5) Notice of Informal P 6) Other:				

Application/Control Number: 10/573,215 Page 2

Art Unit: 1637

### **DETAILED ACTION**

1. Applicant's election without traverse of Group I (claims 1-8) in the reply filed on August 23, 2007 is acknowledged.

#### Status

2. Claims 1-8 are considered for examination. Claim 13 is withdrawn from further consideration pursuant to 37 CFR 1.142(b) as being drawn to a nonelected Group. This is made FINAL.

# Information Disclosure Statement

3. The Information Disclosure Statement filed on June 12, 2006 has been considered.

## **Priority**

4. This application filed on September 19, 2006 is a 371 of PCT/EP04/13627 field on 12/01/04, which claims priority to EPO 03027754.5 filed on 12/02/2003.

#### **Informalities**

- 5. The following informalities are noted:
  - (i) Claim 1 recites 'Method for'. 'A method for' is suggested.
  - (ii) Claim 2 recites 'between 0.1 to 8M'. 'between 0.1 and 8M is suggested.
- (iii) Claims 4, 7 recite 'wherein the incubation temperature . 'wherein the incubation in step d) and step e) is at temperature between  $0^0$  and  $90^0$  C' is suggested.
- (iv) Claims 5, 8 recite 'wherein the incubation time'. 'wherein the incubation in step d) / step e) is between 30min and 48 hours'.

## Claim Rejections - 35 USC § 112

6. The following is a quotation of the second paragraph of 35 U.S.C. 112:

Application/Control Number: 10/573,215

Art Unit: 1637

The specification shall conclude with one or more claims particularly pointing out and distinctly claiming the subject matter which the applicant regards as his invention.

Claims 4-5, 7-8 are rejected under 35 U.S.C. 112, second paragraph, as being indefinite for failing to particularly point out and distinctly claim the subject matter which applicant regards as the invention.

Claims 4-5 and 7-8 recite the limitation "the incubation temperature / the incubation time" in line 2 of the claims. There is insufficient antecedent basis for this limitation in the claim. Claim 1, upon which the instant claims depend recite incubation and the limitation the incubation temperature/ the incubation time' lacks support in the claim 1 upon which they depend. The meets and bounds of the claims is unclear and vague because the independent claim 1 lacks support for said limitations in the instant claims.

# Claim Rejections - 35 USC § 102

- 7. The following is a quotation of the appropriate paragraphs of 35 U.S.C. 102 that form the basis for the rejections under this section made in this Office action:
  - (e) the invention was described in a patent granted on an application for patent by another filed in the United States before the invention thereof by the applicant for patent, or on an international application by another who has fulfilled the requirements of paragraphs (1), (2), and (4) of section 371(c) of this title before the invention thereof by the applicant for patent.

The changes made to 35 U.S.C. 102(e) by the American Inventors Protection Act of 1999 (AIPA) and the Intellectual Property and High Technology Technical Amendments Act of 2002 do not apply when the reference is a U.S. patent resulting directly or indirectly from an international application filed before November 29, 2000. Therefore, the prior art date of the

Art Unit: 1637

reference is determined under 35 U.S.C. 102(e) prior to the amendment by the AIPA (pre-AIPA 35 U.S.C. 102(e)).

Claims 1-8 are rejected under 35 U.S.C. 102(e) as being anticipated by Zon et al. (US Pub No.2005/0153308 A1).

Zon et al. teach a method of claim 1, for the coversion of a cytosine base in a nucleic acid to an uracil base comprising

- (a) providing a solution that contains a nucleic acid (see at least page 1, paragraph 0007, 0013, page 2, paragraph 0014);
- (b) providing guanidinium hydrogen sulfite (bisulfite (=hydrogen sulfite) + guanidine compound) and preparing a solution comprising guanidinium and sulfite ions (see at least page 1, paragraph 0007-0010, 0013, page 2, paragraph 0022, 0025);
  - (c) mixing the solutions from step (a) and (b) (see at least page 1, paragraph 0007, 0013);
- (d) incubating the solution obtained in step (c) containing the nucleic acid and guanidinium and sulfite ions whereby the nucleic acid is deaminated (see at least page 2, paragraph 0014, page 3, paragraph 0041);
- (e) incubating the deaminated nucleic acid under alkaline conditions whereby the deaminated nucleic acid is desulfonated (see at least page 2, paragraph 0015);
  - (f) isolating the deaminated nucleic acid (see at least page 3, paragraph 0041).

With regard to claim 2, Zon et al. teach that the cocentration of guanidinium ions and sulfite ions is between 0.1 and 8M (see at least page 1-2, paragraph 0013).

With regard to claim 3, Zon et al. teach that the pH of solutions in step (b) and step (c) is less than 7.0 (see at least page 4, paragraph 0044, and 0047, table 1).

Application/Control Number: 10/573,215 Page 5

Art Unit: 1637

With regard to claims 4-5, 7-8, Zon et al teach the incubation temperature is between 0<sup>0</sup> C and 90° C (see at least page 2, paragraph 0014).

With regard to claim 6, Zon et al. teach that the step (e) is performed by adding an alkaline solution (see at least page 2, paragraph 0015). Accordingly Zon et al. anticipates the instant claims.

#### Conclusion

No claims are allowable.

Any inquiry concerning this communication or earlier communications from the examiner should be directed to Suryaprabha Chunduru whose telephone number is 571-272-0783. The examiner can normally be reached on 8.30A.M. - 4.30P.M, Mon - Friday,.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Gary Benzion can be reached on 571-272-0782. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300.

Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see http://pair-direct.uspto.gov. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free).

Suryaprabha Chunduru **Primary Examiner** Art Unit 1637